Rechelle never thought her body would let her down. She was 35, living in London with a dream job. She was even making plans ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...

Obesity is not a personal moral failing. It is a complex, multi-factorial condition driven by genetics, environment, and a ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

RELATED: Doctors Warn That Drugs Like Ozempic Are Making You “Skinny Fat.” Any time a person suddenly loses weight, they are ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

As the popularity of the type-2 diabetes drugs have risen, researcher have been looking into different aspects of it to ensure safety. One such research has shown that it could help prevent cognitive ...